AstraZeneca/£AZN

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Ticker

£AZN
Sector

Primary listing

LSE

Employees

94,300

AstraZeneca Metrics

BasicAdvanced
£199B
32.38
£3.96
0.15
£2.45
1.91%

What the Analysts think about AstraZeneca

Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.

Bulls say / Bears say

Second-quarter 2025 revenue rose 11% year-on-year to $14.46 billion and core EPS reached $2.17, both surpassing analyst forecasts and underscoring robust top-line and profitability momentum (Reuters)
Oncology product sales climbed 18% to $6.31 billion, led by strong performances from Tagrisso, Lynparza, and Imfinzi, outperforming expectations and validating its oncology-centric strategy (Reuters)
Baxdrostat met the primary endpoint in a late-stage Phase III trial for treatment-resistant hypertension, paving the way for regulatory filings by year-end 2025 and targeting over $5 billion in peak annual sales (Reuters)
Faces potential import tax fine of up to $8 million in China over suspected unpaid Enhertu import taxes, risking penalties and disruptions in a market representing about 12% of sales (Reuters)
Despite beating Q2 expectations, AstraZeneca maintained its full-year outlook due to ongoing pricing pressures and global trade uncertainties, signaling potential headwinds to revenue growth (Reuters)
Delay of late-stage AVANZAR lung cancer trial data to the first half of 2026 postpones anticipated oncology revenue contributions, introducing timing risk for its pipeline-driven growth (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

AstraZeneca Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AstraZeneca Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £AZN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs